Galectin-3: Presurgical marker of thyroid follicular epithelial cell-derived carcinomas

[1]  A. Raz,et al.  Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis , 2004, Cancer and Metastasis Reviews.

[2]  T. Takano,et al.  Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors. , 2003, Cancer letters.

[3]  Yoshifumi Yamamoto,et al.  Malignant transformation of thyroid follicular cells by galectin-3. , 2003, Cancer letters.

[4]  Yuri E Nikiforov,et al.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[5]  Grace C H Yang,et al.  Should cytopathologists stop reporting follicular neoplasms on fine‐needle aspiration of the thyroid? , 2003, Cancer.

[6]  J. Garber,et al.  Genetic and biological subgroups of low-stage follicular thyroid cancer. , 2003, The American journal of pathology.

[7]  Jen-Der Lin,et al.  Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. , 2003, Cancer letters.

[8]  M. Papotti,et al.  Methodological considerations regarding the use of galectin-3 expression analysis in preoperative evaluation of thyroid nodules. , 2003, The Journal of clinical endocrinology and metabolism.

[9]  L. Hegedüs,et al.  Management of simple nodular goiter: current status and future perspectives. , 2003, Endocrine reviews.

[10]  R.-Y. Yang,et al.  Galectins in cell growth and apoptosis , 2003, Cellular and Molecular Life Sciences CMLS.

[11]  E. Kimura,et al.  Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[12]  Y. Vaishnav,et al.  Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. , 2002, The Journal of clinical endocrinology and metabolism.

[13]  M. Niedziela,et al.  Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. , 2002, The Journal of clinical endocrinology and metabolism.

[14]  S. Aversa,et al.  Role of fine‐needle aspiration biopsy and frozen‐section evaluation in the surgical management of thyroid nodules , 2002, The British journal of surgery.

[15]  Z. Baloch,et al.  Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. , 2002, Archives of pathology & laboratory medicine.

[16]  H. Harms,et al.  Fine needle aspiration of the thyroid: can an image processing system improve differentiation? , 2002, Analytical and quantitative cytology and histology.

[17]  Anna Crescenzi,et al.  Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. , 2002, The Journal of clinical endocrinology and metabolism.

[18]  B. Haugen,et al.  Towards improving the utility of fine‐needle aspiration biopsy for the diagnosis of thyroid tumours , 2002, Clinical endocrinology.

[19]  S. Raphael.  The meanings of markers: Ancillary techniques in diagnosis of thyroid neoplasia , 2002, Endocrine pathology.

[20]  P. De Giuli,et al.  Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[21]  J. Safer,et al.  Twenty-one-gauge needles provide more cellular samples than twenty-five-gauge needles in fine-needle aspiration biopsy of the thyroid but may not provide increased diagnostic accuracy. , 2001, Thyroid : official journal of the American Thyroid Association.

[22]  A. Vecchione,et al.  Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions , 2001, The Lancet.

[23]  K. Wakasa,et al.  The Value of Ultrasound-Guided Fine-Needle Aspiration Cytology for Thyroid Nodules: An Assessment of Its Diagnostic Potential and Pitfalls , 2001, Surgery Today.

[24]  R. Lloyd.  Distinguishing benign from malignant thyroid lesions: Galectin 3 as the latest candidate , 2001, Endocrine pathology.

[25]  A. Longatto-Filho,et al.  Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas , 2001, Endocrine pathology.

[26]  H. Sand Hansen,et al.  Thyroperoxidase (TPO) immunostaining of the solitary cold thyroid nodule , 2000, Clinical endocrinology.

[27]  A. Pontecorvi,et al.  Molecular biology of thyroid neoplasms. , 2000, Rays.

[28]  S. Sukumar,et al.  Human Telomerase Reverse Transcriptase ( hTERT ) Gene Expression in Thyroid Neoplasms 1 , 1999 .

[29]  G. Botti,et al.  Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. , 1998, Cancer research.

[30]  P. De Giuli,et al.  Galectin-3 is a presurgical marker of human thyroid carcinoma. , 1998, Cancer research.

[31]  S. Savin,et al.  Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. , 1998, Anticancer research.

[32]  H. Suárez.  Genetic alterations in human epithelial thyroid tumours , 1998, Clinical endocrinology.

[33]  A. Kovatich,et al.  Immunocytochemical evaluation of HBME‐1, CA 19‐9, and CD‐15 (Leu‐M1) in fine‐needle aspirates of thyroid nodules , 1998, Diagnostic cytopathology.

[34]  M. Sack,et al.  HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[35]  K. Kashima,et al.  Cytoplasmic biotin-like activity interferes with immunohistochemical analysis of thyroid lesions: a comparison of antigen retrieval methods. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[36]  E. Campo,et al.  GALECTIN‐3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON‐NEOPLASTIC THYROID TISSUE , 1997, The Journal of pathology.

[37]  H. Inohara,et al.  Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. , 1996, Cancer research.

[38]  L. Trusolino,et al.  Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. , 1996, Journal of the National Cancer Institute.

[39]  R. Lotan,et al.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. , 1995, The American journal of pathology.

[40]  John L. Wang,et al.  Identification of galectin-3 as a factor in pre-mRNA splicing. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[41]  L. Skoog,et al.  Thyroid peroxidase immunodetection as a tool to assist diagnosis of thyroid nodules on fine-needle aspiration biopsy. , 1994, European journal of endocrinology.

[42]  S. Barondes,et al.  Galectins. Structure and function of a large family of animal lectins. , 1994, The Journal of biological chemistry.

[43]  S. Sato,et al.  Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. , 1994, The Journal of biological chemistry.

[44]  N. Sneige,et al.  Diagnostic pitfalls in thyroid fine‐needle aspiration: A review of 394 cases , 1993, Diagnostic cytopathology.

[45]  E. Mazzaferri,et al.  Management of a solitary thyroid nodule. , 1993, The New England journal of medicine.

[46]  J. Rosai,et al.  Tumors of the thyroid gland , 1992 .

[47]  J. Hamming,et al.  The value of fine-needle aspiration biopsy in patients with nodular thyroid disease divided into groups of suspicion of malignant neoplasms on clinical grounds. , 1990, Archives of internal medicine.

[48]  Harlan I. Firminger,et al.  Atlas of tumor pathology , 1954 .